Guselkumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Guselkumab" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

4doi.org

2^nd place

4web.archive.org

1^st place

2jnj.com

low place

2fda.gov

447^th place

338^th place

2hpfb-dgpsa.ca

low place

2canada.ca

1,712^th place

1,063^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1medlineplus.gov

1,581^st place

1,299^th place

1semanticscholar.org

11^th place

8^th place

1genengnews.com

low place

6,625^th place

1pharmabiz.com

low place

1mdedge.com

low place

1bloomberg.com

99^th place

77^th place

1fiercepharma.com

low place

8,921^st place

1clinicaltrials.gov

5,225^th place

4,062^nd place

bloomberg.com

"DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis". Bloomberg.com. 14 July 2020. Retrieved 6 September 2020.

canada.ca

health-products.canada.ca

"Product information". health-products.canada.ca. 27 November 2017. Retrieved 18 March 2024.

canada.ca

"Skin health". Health Canada. 9 May 2018. Retrieved 13 April 2024.

clinicaltrials.gov

Janssen Research & Development, LLC (11 August 2017). A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (Report). clinicaltrials.gov.{{cite report}}: CS1 maint: multiple names: authors list (link)

doi.org

Kim PJ, Lansang RP, Vender R (July 2023). "A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections". Journal of Cutaneous Medicine and Surgery. 27 (4): 358–367. doi:10.1177/12034754231188444. PMC 10486173. PMID 37533141.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. (November 2000). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity. 13 (5): 715–725. doi:10.1016/S1074-7613(00)00070-4. PMID 11114383.{{cite journal}}: CS1 maint: overridden setting (link)
Markham A (September 2017). "Guselkumab: First Global Approval". Drugs. 77 (13): 1487–1492. doi:10.1007/s40265-017-0800-7. PMID 28819723. S2CID 35810454.
Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, et al. (September 2017). "Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials". Dermatology and Therapy. 7 (3): 281–292. doi:10.1007/s13555-017-0187-0. PMC 5574739. PMID 28639011.{{cite journal}}: CS1 maint: overridden setting (link)

europa.eu

ema.europa.eu

"European Medicines Agency". European Medicines Agency {EMA). 17 September 2018. Retrieved 12 June 2021.

fda.gov

"TREMFYA". Drug Approvals and Databases > Drug Trials Snapshots. U.S. Food and Drug Administration. 3 August 2017. Archived from the original on 2 November 2017.
"Novel Drug Approvals for 2017". U.S. Food and Drug Administration (FDA). 25 January 2021. Archived from the original on 1 February 2017.

fiercepharma.com

Helfand C (13 July 2017). "Johnson & Johnson's Tremfya gets its go-ahead to fight Novartis, Lilly in psoriasis. Can it stand out?". Fierce Pharma.

genengnews.com

"Janssen Wins FDA Approval for Plaque Psoriasis Treatment Tremfya". Genetic Engineering & Biotechnology News. 14 July 2017.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Tremfya". Drug and Health Products Portal. 10 November 2017. Retrieved 18 March 2024.
"Regulatory Decision Summary for Tremfya". Drug and Health Products Portal. 4 September 2020. Retrieved 18 March 2024.

jnj.com

"Tremfya (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease" (Press release). Johnson & Johnson.
"Janssen Submits Application to EMA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis" (Press release). Janssen. Archived from the original on 7 November 2017. Retrieved 1 November 2017.

mdedge.com

"FDA approves Tremfya (guselkumab) for psoriatic arthritis". www.mdedge.com. Retrieved 15 July 2020.

medicines.org.uk

"Tremfya 100 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 1 November 2020. Retrieved 12 June 2021.

medlineplus.gov

"Guselkumab Injection". MedlinePlus Drug Information.

nih.gov

pubmed.ncbi.nlm.nih.gov

"Guselkumab". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. June 2018. PMID 31643594.
Kim PJ, Lansang RP, Vender R (July 2023). "A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections". Journal of Cutaneous Medicine and Surgery. 27 (4): 358–367. doi:10.1177/12034754231188444. PMC 10486173. PMID 37533141.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. (November 2000). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity. 13 (5): 715–725. doi:10.1016/S1074-7613(00)00070-4. PMID 11114383.{{cite journal}}: CS1 maint: overridden setting (link)
Markham A (September 2017). "Guselkumab: First Global Approval". Drugs. 77 (13): 1487–1492. doi:10.1007/s40265-017-0800-7. PMID 28819723. S2CID 35810454.
Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, et al. (September 2017). "Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials". Dermatology and Therapy. 7 (3): 281–292. doi:10.1007/s13555-017-0187-0. PMC 5574739. PMID 28639011.{{cite journal}}: CS1 maint: overridden setting (link)

ncbi.nlm.nih.gov

Kim PJ, Lansang RP, Vender R (July 2023). "A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections". Journal of Cutaneous Medicine and Surgery. 27 (4): 358–367. doi:10.1177/12034754231188444. PMC 10486173. PMID 37533141.
Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, et al. (September 2017). "Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials". Dermatology and Therapy. 7 (3): 281–292. doi:10.1007/s13555-017-0187-0. PMC 5574739. PMID 28639011.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Tremfya- guselkumab injection". DailyMed. Retrieved 22 January 2021.

pharmabiz.com

"MorphoSys' licensee Janssen receives Japanese approval for Tremfya to treat moderate to severe forms of psoriasis & psoriatic arthritis". pharmabiz.com. Archived from the original on 29 April 2021. Retrieved 5 June 2018.

semanticscholar.org

api.semanticscholar.org

Markham A (September 2017). "Guselkumab: First Global Approval". Drugs. 77 (13): 1487–1492. doi:10.1007/s40265-017-0800-7. PMID 28819723. S2CID 35810454.

tga.gov.au

ebs.tga.gov.au

"Tremfya (Guselkumab) Australian Product Information". Department of Health, Therapeutic Goods Administration. The Australian Government.

web.archive.org

"TREMFYA". Drug Approvals and Databases > Drug Trials Snapshots. U.S. Food and Drug Administration. 3 August 2017. Archived from the original on 2 November 2017.
"Janssen Submits Application to EMA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis" (Press release). Janssen. Archived from the original on 7 November 2017. Retrieved 1 November 2017.
"Novel Drug Approvals for 2017". U.S. Food and Drug Administration (FDA). 25 January 2021. Archived from the original on 1 February 2017.
"MorphoSys' licensee Janssen receives Japanese approval for Tremfya to treat moderate to severe forms of psoriasis & psoriatic arthritis". pharmabiz.com. Archived from the original on 29 April 2021. Retrieved 5 June 2018.